Who Can Actually Afford Their NHS Prescriptions?

England dispenses 1.1 billion prescription items each year — more than 17 per person — at a total net ingredient cost of £10.8 billion. The prescription charge stands at £9.90 per item (April 2024), up 60% in real terms since 2000. Yet 90% of items are dispensed free: the over-60s account for 43% of all items, those holding medical exemption certificates a further 31%. The charge, in practice, falls almost entirely on working-age adults without qualifying conditions. An estimated 750,000 people skip or cut prescribed medication each year due to cost, according to the Prescription Charges Coalition — a rationing effect invisible to the health system that manages it.

The charge creates a stark devolution divide. Scotland abolished prescription charges in 2011, Wales in 2007, Northern Ireland in 2010. England alone maintains the levy, affecting the 10% of patients who pay — predominantly working-age adults presenting one or two items with no qualifying exemption. The most exposed are those whose chronic conditions do not appear on the medical exemption certificate list: mental health conditions, musculoskeletal problems, and many chronic pain disorders all fall outside it. The Prescription Prepayment Certificate (£111.60 a year for unlimited items) protects frequent users but requires upfront payment that many cannot afford. Black and Asian patients, more likely to be in working age without exemption, pay charges at proportionally higher rates.

NHS England's medicines optimisation programme delivered savings of £540 million in 2022/23 through biosimilar switching and formulary management — demonstrating that clinical equivalence and cost discipline can coexist. But NICE's cost-effectiveness threshold of £20,000–£30,000 per quality-adjusted life year continues to restrict access to cancer drugs and rare disease treatments routinely available in France and Germany. The Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) caps the overall branded medicines bill. A 2023 petition to abolish prescription charges in England attracted 145,000 signatures; the government rejected it, citing annual revenue of approximately £570 million — roughly 0.4% of the NHS England budget, and a figure dwarfed by the downstream costs of non-adherence.

The cost burden is concentrated among a specific and identifiable group: working-age adults aged 18–59 with chronic conditions not listed on the medical exemption certificate. The exemption list, last substantively updated in 1968, covers conditions such as diabetes, hypothyroidism, and epilepsy, but excludes asthma, Crohn's disease, rheumatoid arthritis, depression, and chronic pain. A patient with rheumatoid arthritis requiring methotrexate, folic acid, and anti-inflammatory medication faces charges of £29.70 per month — £356.40 annually — unless they purchase the prepayment certificate. For patients on multiple medications across different conditions, costs accumulate rapidly. The geographic dimension is less discussed: prescription charge revenue is highest per capita in areas of the Midlands and North where chronic disease prevalence is greatest and household incomes lowest. Universal Credit recipients are exempt, but those earning just above the threshold — the “working poor” — are fully exposed. The non-adherence this produces generates downstream NHS costs that the Department of Health has never formally quantified.

The 750,000 figure for patients skipping medication due to cost, widely cited by campaigners and in parliamentary debate, originates from a 2017 Prescription Charges Coalition survey with a self-selected sample and has not been updated with a robust, nationally representative study. NHS Business Services Authority data captures what is dispensed but not what is prescribed and never collected — the gap between prescribing and dispensing is a known blind spot. There is no routine national data on prescription charge-related non-adherence, meaning the true scale of cost-driven rationing is unknown. The exemption system itself generates a measurement artefact: because 90% of items are free, the “average cost per item” figure is meaningless for the 10% who actually pay. International comparison is complicated by differing charging models — France operates a reimbursement system, Germany uses co-payments capped at 2% of income, and no directly equivalent metric exists. The annual £570 million revenue figure cited by government does not net off the administrative cost of managing the exemption and prepayment system, nor the health service costs attributable to non-adherence, making any cost-benefit analysis of abolition inherently incomplete.